Skip to content

Neuromodulation

TL;DR — Neuromodulation spans non-invasive cortical stimulation and implanted SCS/DRG systems. In refractory painful diabetic neuropathy, 10-kHz SCS plus conventional care improved six-month response in a selected randomized population (Petersen 2021, PMID 33818600); broader chronic-pain evidence remains uncertain and procedure harms accumulate (O'Connell 2021, PMID 34854473).

Modalities

SCS stimulates dorsal columns/networks; DRG stimulation targets segmental ganglia; rTMS/tDCS stimulate cortical circuits; TENS stimulates peripheral afferents.

These modalities should not be collapsed into a single “neuromodulation” effect. Implantable systems deliver continuous or programmed energy through surgically placed leads; rTMS and tDCS deliver repeated time-limited cortical sessions; TENS is peripheral, user-operated and inexpensive. Their sham credibility, reversibility, adverse-event horizon and cost differ by orders of magnitude (Sdrulla 2018, PMID 29526043); (da Cunha 2024, PMID 39580221).

Modality Anatomical level Typical evidence unit Central interpretive problem
Conventional SCS Dorsal columns and distributed spinal/supraspinal circuits Trial implant followed by permanent system Paresthesia can unmask assignment
10-kHz SCS Thoracic epidural stimulation without intended paresthesia Randomized CMM comparison Invasive sham and crossover are difficult
DRG stimulation Segmental dorsal-root ganglion Comparative device trial/observational cohort Evidence concentrated in focal lower-limb syndromes
Motor-cortex rTMS Cortical network Repeated sham-controlled sessions Coil, target, frequency and maintenance vary
tDCS Cortical network Weak-current sham-controlled sessions Small effects and imperfect sham at higher current
TENS Peripheral afferents Home-device trial Dose, adherence and blinding are inconsistent

Selection

Confirm neuropathic diagnosis, optimize less invasive care, define functional goals, assess psychological/comorbidity risk and document infection/bleeding constraints.

Painful diabetes

The SENZA-PDN randomized trial supports 10-kHz SCS at six months (Petersen 2021, PMID 33818600); later overview emphasizes durability questions (Petersen 2023, PMID 38245324).

SENZA-PDN randomized 216 participants with refractory painful diabetic neuropathy. At six months, the composite primary outcome—≥50% pain relief without worsening neurologic deficit—occurred in 79% with 10-kHz SCS plus conventional medical management and 5% with medical management alone; infection requiring explant occurred in 2% (Petersen 2021, PMID 33818600). The magnitude is striking, but the comparator was not an invasive sham and participants were selected as implant candidates.

Among 142 implanted participants assessed at 24 months after initial assignment or crossover, pain severity was 66.9% lower and pain interference 65.8% lower than preimplantation, with 91.5% reporting satisfaction (Petersen 2026, PMID 39369310). Because the randomized comparison ended at crossover, these long-term within-implant estimates demonstrate durability among retained implanted participants, not maintained randomized superiority.

Protective-sensation analyses reported roughly doubled low-ulcer-risk classification by three months, sustained through 24 months (Argoff 2025, PMID 38193426). This is hypothesis-generating for disease modification: monofilament improvement is a secondary clinical measure and does not yet prove fewer ulcers or amputations.

SCS evidence boundary

Cochrane review found very low-certainty evidence across implanted neuromodulation for chronic pain and insufficient long-term placebo-controlled data (O'Connell 2021, PMID 34854473).

The apparent tension between SENZA-PDN and Cochrane is methodological. A large open-device versus medical-care effect can coexist with very-low-certainty placebo-controlled evidence if implantation, expectation and crossover prevent credible long-term blinding. The appropriate conclusion is indication-specific efficacy in selected PDN plus unresolved device-specific placebo contribution and long-horizon net benefit—not that either evidence source nullifies the other (Petersen 2021, PMID 33818600); (O'Connell 2021, PMID 34854473).

DRG stimulation

DRG may offer focal coverage; systematic reviews are dominated by small and observational cohorts (Nagpal 2021, PMID 33260203); (D'Souza 2022, PMID 35994195).

ACCURATE randomized 152 people with lower-extremity CRPS or causalgia to DRG or conventional SCS. The composite of ≥50% relief without stimulation-related neurologic deficit was achieved by 81.2% with DRG and 55.7% with SCS at three months (P<0.001); device-related and serious adverse events did not differ significantly, and DRG produced less positional paresthesia variation (Deer 2017, PMID 28030470). This comparative result does not establish benefit over sham, nor does it justify extrapolation to diffuse polyneuropathy.

Non-invasive stimulation

A multicenter sham-controlled rTMS trial and meta-analyses show protocol-dependent short-term effects (Attal 2021, PMID 34196698); (Jiang 2022, PMID 34826512).

The 2021 multicenter RCT compared motor-cortex stimulation protocols across peripheral and central neuropathic pain and found protocol- and site-dependent effects, illustrating why “rTMS works” is too coarse a claim (Attal 2021, PMID 34196698). Evidence-based rTMS guidance assigns recommendations to specific target/frequency/condition combinations rather than to the modality globally (Lefaucheur 2020, PMID 31901449). tDCS and TENS syntheses remain limited by small studies, variable dosing and short follow-up (Fregni 2021, PMID 32710772); (Gibson 2017, PMID 28905362).

Selection and trial-to-implant funnel

Stage Required evidence Failure mode to record
Diagnostic confirmation Lesion/disease plus neuroanatomically plausible pain Implanting nonspecific pain without a coherent target
Conservative-treatment review Adequate class trials and functional goals Labeling intolerance as pharmacologic “failure” without dose/duration detail
Procedural risk review Infection, bleeding, glycemic, psychiatric and anatomical assessment Excluding high-risk patients from trials but generalizing results to them
Temporary trial Prespecified pain and functional threshold Treating short trial response as proof of multi-year durability
Permanent implant Shared endpoint set and device plan Counting only implanted responders; omitting failed trials
Long-term surveillance Infection, lead migration/fracture, revision, explant, medication and function Survivorship bias after loss to follow-up

Harms table

Modality Main harms/limitations
SCS Infection, migration, lead failure, revision, explant
DRG Lead fracture/migration, neurologic injury
rTMS Headache, rare seizure, repeated visits
tDCS Skin irritation, uncertain effect size
TENS Low harm, uncertain durable efficacy

Outcome standard

Report responder thresholds, function, medication change, infection, revision, explant and cost over years—not only pain at implant follow-up.

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
33818600 2021 Randomized 10-kHz SCS versus medical management in PDN Invasive-sham effect or broad neuropathic-pain efficacy
39369310 2026 Twenty-four-month implanted-cohort outcomes Maintained randomized superiority after crossover
38193426 2025 Protective-sensation secondary analysis Reduction in ulcers or amputations
34854473 2021 Placebo-control and certainty boundary across implanted systems Indication-specific null effect in PDN
28030470 2017 DRG versus SCS comparative trial in CRPS/causalgia Benefit over sham or in diffuse polyneuropathy
34196698 2021 Multicenter sham-controlled rTMS evidence A class effect across stimulation protocols

Explicit controversies

  1. Large pragmatic effect versus uncertain specific effect. SENZA-PDN reported a 74-percentage-point six-month difference in its composite response (Petersen 2021, PMID 33818600), while Cochrane judged placebo-controlled implanted evidence very uncertain (O'Connell 2021, PMID 34854473). The unresolved issue is how much benefit is attributable to waveform-specific neural action versus implantation and contextual effects.
  2. Disease modification versus sensory measurement change. Improved monofilament sensation after 10-kHz SCS is biologically and clinically interesting (Argoff 2025, PMID 38193426). A 2025 propensity-matched electronic-record cohort associated SCS with fewer below-knee amputations than gabapentinoid-plus-duloxetine therapy (HR 0.19, 95% CI 0.08–0.46), but residual confounding and outcome-code ascertainment preclude a preventive causal claim (Henney 2025, PMID 41079020). A targeted PubMed search on 2026-08-30 found no randomized ulcer/amputation endpoint trial or validated axonal-regeneration mechanism; small QSART/NCS cohorts remain insufficient (Kissoon 2023, PMID 37833046).
  3. DRG precision versus evidence breadth. DRG outperformed conventional SCS in focal CRPS/causalgia (Deer 2017, PMID 28030470), whereas reviews for other lower-extremity neuropathic syndromes remain dominated by small observational series (D'Souza 2022, PMID 35994195).
  4. Repeatable non-invasive treatment versus durability. rTMS can produce short-term benefit under some protocols (Attal 2021, PMID 34196698), but an evidence-based maintenance schedule and durable functional effect are not established.

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • What is five-year net benefit of SCS?
  • Which phenotype favors DRG over SCS?
  • Can sham-controlled implanted trials remain credible?
  • What maintenance schedule sustains rTMS benefit?

References

  1. Petersen EA, Stauss TG, Scowcroft JA, et al.. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021;78:687-698. PMID 33818600
  2. O'Connell NE, Ferraro MC, Gibson W, et al.. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021;12:CD013756. PMID 34854473
  3. Petersen EA. Spinal cord stimulation in painful diabetic neuropathy: An overview. Diabetes Res Clin Pract. 2023;206 Suppl 1:110760. PMID 38245324
  4. Nagpal A, Clements N, Duszynski B, et al.. The Effectiveness of Dorsal Root Ganglion Neurostimulation for the Treatment of Chronic Pelvic Pain and Chronic Neuropathic Pain of the Lower Extremity: A Comprehensive Review of the Published Data. Pain Med. 2021;22:49-59. PMID 33260203
  5. D'Souza RS, Kubrova E, Her YF, et al.. Dorsal Root Ganglion Stimulation for Lower Extremity Neuropathic Pain Syndromes: An Evidence-Based Literature Review. Adv Ther. 2022;39:4440-4473. PMID 35994195
  6. Attal N, Poindessous-Jazat F, De Chauvigny E, et al.. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. Brain. 2021;144:3328-3339. PMID 34196698
  7. Jiang X, Yan W, Wan R, et al.. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132:130-141. PMID 34826512
  8. Sdrulla AD, Guan Y, Raja SN. Spinal Cord Stimulation: Clinical Efficacy and Potential Mechanisms. Pain Pract. 2018;18:1048-1067. PMID 29526043
  9. Fontaine D. Spinal cord stimulation for neuropathic pain. Rev Neurol (Paris). 2021;177:838-842. PMID 34384626
  10. Raghu ALB, Parker T, Aziz TZ, et al.. Invasive Electrical Neuromodulation for the Treatment of Painful Diabetic Neuropathy: Systematic Review and Meta-Analysis. Neuromodulation. 2021;24:13-21. PMID 32588933
  11. Vallejo R, Gupta A, Cedeno DL, et al.. Clinical Effectiveness and Mechanism of Action of Spinal Cord Stimulation for Treating Chronic Low Back and Lower Extremity Pain: a Systematic Review. Curr Pain Headache Rep. 2020;24:70. PMID 32997170
  12. Burkey AR, Chen J, Argoff CE, et al.. Painful Peripheral Neuropathies of the Lower Limbs and/or Lower Extremities Treated with Spinal Cord Stimulation: A Systematic Review with Narrative Synthesis. J Pain Res. 2023;16:1607-1636. PMID 37229154
  13. Vanloon M, Van Broeckhoven T, Raymaekers V, et al.. Noninfectious Complications of Dorsal Root Ganglion Stimulation: A Systematic Review and Meta-Analysis. Neuromodulation. 2025;28:234-248. PMID 39601733
  14. Abd-Elsayed A, Vardhan S, Aggarwal A, et al.. Mechanisms of Action of Dorsal Root Ganglion Stimulation. Int J Mol Sci. 2024;25. PMID 38612402
  15. Graham RD, Sankarasubramanian V, Lempka SF. Dorsal Root Ganglion Stimulation for Chronic Pain: Hypothesized Mechanisms of Action. J Pain. 2022;23:196-211. PMID 34425252
  16. Bremer N, Ruby J, Weyker PD, et al.. Neuromodulation: a focus on dorsal root ganglion stimulation. Pain Manag. 2016;6:205-9. PMID 26975305
  17. Lefaucheur JP, Aleman A, Baeken C, et al.. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020;131:474-528. PMID 31901449
  18. Fregni F, El-Hagrassy MM, Pacheco-Barrios K, et al.. Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders. Int J Neuropsychopharmacol. 2021;24:256-313. PMID 32710772
  19. Lefaucheur JP, Antal A, Ayache SS, et al.. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017;128:56-92. PMID 27866120
  20. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;9:CD011976. PMID 28905362
  21. Mokhtari T, Ren Q, Li N, et al.. Transcutaneous Electrical Nerve Stimulation in Relieving Neuropathic Pain: Basic Mechanisms and Clinical Applications. Curr Pain Headache Rep. 2020;24:14. PMID 32072323
  22. Li S, Stampas A, Frontera J, et al.. Combined transcranial direct current stimulation and breathing-controlled electrical stimulation for management of neuropathic pain after spinal cord injury. J Rehabil Med. 2018;50:814-820. PMID 30132010
  23. Uzunköprü C. Invasive Therapies in Multiple Sclerosis. Noro Psikiyatr Ars. 2018;55:S21-S25. PMID 30692850
  24. da Cunha PHM, Lapa JDDS, Hosomi K, et al.. Neuromodulation for neuropathic pain. Int Rev Neurobiol. 2024;179:471-502. PMID 39580221
  25. Moisset X, Bouhassira D, Avez Couturier J, et al.. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325-352. PMID 32276788
  26. Petersen EA, Stauss TG, Scowcroft JA, et al. High-frequency 10-kHz spinal cord stimulation provides long-term (24-month) improvements in diabetes-related pain and quality of life for patients with painful diabetic neuropathy. J Diabetes Sci Technol. 2026;20:124-133. PMID 39369310
  27. Argoff CE, Armstrong DG, Kagan ZB, et al. Improvement in protective sensation: clinical evidence from a randomized controlled trial for treatment of painful diabetic neuropathy with 10 kHz spinal cord stimulation. J Diabetes Sci Technol. 2025;19:992-998. PMID 38193426
  28. Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158:669-681. PMID 28030470
  29. Kissoon NR, LeMahieu AM, Stoltenberg AD, et al. Quantitative assessment of painful diabetic peripheral neuropathy after high-frequency spinal cord stimulation: a pilot study. Pain Med. 2023;24 Suppl 2:S41-S47. PMID 37833046
  30. Henney AE, Frank B, Riley DR, et al. Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study. EClinicalMedicine. 2025;89:103489. PMID 41079020